New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
09:25 EDTAVTH, AVTH, SSET, SSET, AWK, AWK, NBS, NBS, SNWV, SNWV, ATNM, ATNM, VTEQ, VTEQ, AKER, AKER, CGIX, CGIX, DIRI, DIRIRedChip Companies to hold a virtual conference
Global Online CEO Conference to be held on July 16-17 with webcasted presentations to begin on July 16 at 9:30 am. Webcast Link
News For AVTH;CGIX;AKER;VTEQ;ATNM;SNWV;NBS;AWK;SSET;DIRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2015
07:12 EDTAKER, CGIX, AWK, AVTH, ATNMRedChip Companies to hold a virtual conference
Subscribe for More Information
January 27, 2015
10:00 EDTAWKOn the Fly: Analyst Downgrade Summary
Subscribe for More Information
07:20 EDTAWKAmerican Water downgraded to Neutral from Buy at Ladenburg
Ladenburg downgraded American Water to Neutral with a $58 price target.
January 26, 2015
07:12 EDTATNMActinium submits pre-IND meeting request to FDA for Iomab-B drug candidate
Subscribe for More Information
07:10 EDTAKERAkers Biosciences granted European patent for blood separator technology
Akers Biosciences announces that the European Patent Office has issued a patent surrounding the company's novel blood separator technology and method of separating a fluid fraction from whole blood. Akers was granted U.S. patent protection for the Technology in 2011. The Technology, developed and wholly owned by Akers, enables rapid blood cell separation of small volumes of whole blood, including those obtained from finger stick samples. By utilizing the Technology, serum or plasma samples are extracted within 30-90 seconds and are ready for immediate analysis. By contrast, conventional methods of blood cell separation are labor-intensive and time consuming, taking 30-120 minutes, and typically involving blood collection and laboratory personnel as well as electrically-powered centrifuges and other specialized equipment. The Technology, which further accelerates the rate at which a test result is obtained, is marketed by Akers under the brand name seraSTAT and forms a key component of the company's PIFA product range. In addition to seraSTAT's incorporation within some of the company's own diagnostic tests, Akers intends to license its proprietary blood separator Technology to third parties seeking to accelerate their own testing procedures by facilitating the blood cell separation process as a component of their test.
January 21, 2015
11:42 EDTAWKCPUC pact an incremental positive for California exposed names, says Wells Fargo
Subscribe for More Information
11:36 EDTAWKAmerican Water announces one-year extension in Cost of Capital filing with CPUC
Subscribe for More Information
January 20, 2015
07:33 EDTNBSNeoStem receives drug manufacture license for Irvine, CA facility
NeoStem announced that the State of California's Department of Public Health, Food and Drug Branch has completed its review of NeoStem's manufacturing and control processes at its Irvine, California cGMP facility for the production of eltrapuldencel-T and has issued NeoStem a manufacturing license permitting NeoStem to manufacture drugs from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the company's patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.
07:06 EDTATNMActinium submits CMC meeting request to FDA for Iomab-B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use